Second malignancies in long-term testicular cancer survivors

International Urology and Nephrology

Volumn 46, Issue 4, 2014, Pages 749-756

  Ondrus, D ^a   Ondrusova, M ^b,c   Friedova, L ^d  

^a Faculty of Natural Sciences   (Slovakia)

^b St Elizabeth University College of Health and Social Sciences   (Slovakia)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

^d Bratislava   (Slovakia)

Author keywords

Chemotherapy; Diagnostic radiation exposure; Radiotherapy; Second malignancies; Testicular cancer

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CANCER THERAPY; COLORECTAL CANCER; HUMAN; KIDNEY CANCER; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PROSTATE CANCER; SECOND CANCER; SEMINOMA; STANDARDIZED INCIDENCE RATIO; TESTIS CANCER; AGE; COLORECTAL NEOPLASMS; EPIDEMIOLOGY; FOLLOW UP; INCIDENCE; KIDNEY NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; PROSTATIC NEOPLASMS; SLOVAKIA; SURVIVOR; TESTICULAR NEOPLASMS; TIME; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; ORCHIECTOMY; PROSTATIC NEOPLASMS; SEMINOMA; SLOVAKIA; SURVIVORS; TESTICULAR NEOPLASMS; TIME FACTORS; YOUNG ADULT;

EID: 84897547618     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-013-0554-4     Document Type: Article

References (21)

1. Ondrusova M, Plesko I, Safaei-Diba C, Obsitnikova A, Stefanakova D, Ondrus D (2007) Comprehensive analysis of incidence and mortality of malignant tumours in the Slovak Republic [online]. NCR SR, NHIC, Bratislava. http://www.nor-sk.org/
2. Safaei-Diba C, Plesko I, Frindtova V, Kopecka I, Krakovska B et al (2008) Cancer incidence in the Slovak Republic 2004. NCR SR, NHIC, Bratislava
3. Safaei-Diba C, Plesko I, Obsitnikova A, Dienerova M, Kalmancokova A et al (2009) Cancer incidence in the Slovak Republic 2005. NCR SR, NHIC, Bratislava
4. Safaei-Diba C, Plesko I, Hlava P (eds) (2010) Cancer incidence in the Slovak Republic 2006. NCR SR, NHIC, Bratislava
5. Safaei-Diba C, Plesko I, Hlava P (eds) (2012) Cancer incidence in the Slovak Republic 2007. NCR SR, NHIC, Bratislava
6. National Cancer Institute: Surveillance Research. Cancer Control and Population Sciences (2013) http://surveillance.cancer.gov/joinpoint/
7. Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for join point regression with applications to cancer rates. Stat Med 19:335-351
8. Hemminki K, Liu H, Sundquist J (2010) Second cancers after testicular cancer diagnosed after 1980 in Sweden. Ann Oncol 21:1546-1551
9. Zwahlen DR, Martin JM, Millar JL, Schneider U (2008) Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 70:853-858
10. Lawrentschuk N, Gyomber D, Bolton DM (2006) Renal cell carcinoma following testicular cancer: case report and literature review. Int Urol Nephrol 38:1-4
11. Richiardi L, Scélo G, Boffetta P, Hemminki K, Pukkala E et al (2007) Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 120:623-631
12. Travis LB, Fosså SD, Schonfeld SJ, Mc Master ML, Lynch CF et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Nat Cancer Inst 97:1354-1365
13. Tseng TS, Lin HY, Moody-Thomas S, Martin M, Chen T (2012) Who tended to continue smoking after cancer diagnosis: the National Health and Nutrition Examination Survey 1999-2008. BMC Public Health 12(784):1-9
14. Robinson D, Møller H, Horwich A (2007) Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 96:529-533
15. Büchler T, Kubankova P, Boublikova L, Donatova Z, Foldyna M et al (2011) Detection of second malignancies during long-term follow-up of testicular cancer survivors. Cancer 117:4212-4218
16. Simone CB, Kramer K, O'Meara WP, Bekelman JE, Belard A et al (2012) Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys 82:242-249
17. Schairer C, Hisada M, Chen BE, Brown LM, Fosså SD et al (2007) Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Nat Cancer Inst 99:1248-1256
18. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydøy M et al (2012) Long-term and late effects of germ cell testicular cancer treatment and implication for follow-up. J Clin Oncol 30:3752-3763
19. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2000) Some antiviral and antineoplastic drugs, and other pharmaceutical agents, IARC Monographs on the evaluation of carcinogenic risks to humans. IARC Press, Lyon
20. Van Leeuwen FE, Stiggelbout AM, Van den Belt-Dusebout AW, Noyon R, Eliel MR et al (1993) Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 11:415-424
21. Van Walraven C, Fergusson D, Earle C, Baxter N, Alibhai S et al (2011) Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol 29:2883-2888